Shanghai Fosun And Chindex CEO Team Up To Capitalize On China’s Growing Private Markets

18 Feb 2014

As China opens up its private hospital market and a new wave of investment, major players such as Chindex International Inc. are reevaluating and repositioning themselves to benefit from the growing private infrastructure.

BEIJING – Another U.S.-listed and China-focused health care firm is going private. Chindex International Inc. announced Feb. 17 that it has agreed to be acquired by a buyer consortium of private investment firm TPG, Shanghai Fosun Pharmaceutical Group Co. Ltd. and Roberta Lipson, Chindex’s CEO, in a transaction valued at roughly $369 million.

Under terms of the agreement, the consortium will acquire all outstanding shares of Chindex’s common stock at $19.50 per share,...